Back to Search
Start Over
APABETALONE, AN EPIGENETIC BET INHIBITOR IN A PHASE 3 TRIAL, INHIBITS VASCULAR INFLAMMATION AND CELLULAR ADHESION LEADING TO BENEFICIAL OUTCOMES IN CVD PATIENTS
- Source :
- Journal of the American College of Cardiology. 73:2063
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Apabetalone (RVX-208) is a small molecule bromodomain & extraterminal (BET) protein inhibitor, targeting the second bromodomain (BD2) of BET proteins. In cardiovascular disease (CVD) patients enrolled in phase 2 trials apabetalone treatment reduced the relative risk of a CV event by 44% (Nicholls
Details
- ISSN :
- 07351097
- Volume :
- 73
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi...........85a7155d1adc8ca1d45cc1dde8607479